Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterized by aberrant signaling in the RAS/MAPK signaling cascade. Understanding the mechanisms of HCM development in such RASopathies may lead to novel therapeutic strategies, but relevant experimental models of the human condition are lacking. Therefore, the objective of this study was to develop the first 3D human engineered cardiac tissue (hECT) model of HCM. The hECTs were created using human cardiomyocytes obtained by directed differentiation of induced pluripotent stem cells derived from a patient with CFCS due to an activating BRAF mutation. The mutant myocytes were directly conjugated at a 3:1 ratio with a stromal cell population to create a tissue of defined composition. Compared to healthy patient control hECTs, BRAF-hECTs displayed a hypertrophic phenotype by culture day 6, with significantly increased tissue size, twitch force, and atrial natriuretic peptide (ANP) gene expression. Twitch characteristics reflected increased contraction and relaxation rates and shorter twitch duration in BRAF-hECTs, which also had a significantly higher maximum capture rate and lower excitation threshold during electrical pacing, consistent with a more arrhythmogenic substrate. By culture day 11, twitch force was no longer different between BRAF and wild-type hECTs, revealing a temporal aspect of disease modeling with tissue engineering. Principal component analysis identified diastolic force as a key factor that changed from day 6 to day 11, supported by a higher passive stiffness in day 11 BRAF-hECTs. In summary, human engineered cardiac tissues created from BRAF mutant cells recapitulated, for the first time, key aspects of the HCM phenotype, offering a new in vitro model for studying intrinsic mechanisms and screening new therapeutic approaches for this lethal form of heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast to prior cardiac disease modeling approaches focused on genetic mutations, 20,42,43 this study demonstrates the use of biologics for induction of disease without requiring patient-specific human induced pluripotent stem cells.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdi, H., & Williams, L. J. (2010) · WIREs Computational Statistics · doi:10.1002/wics.101 · Cited by 11,104
What is principal component analysis?
Ringnér, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0308-303 · Cited by 2,407
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Rauen, K. A. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153523 · Cited by 879 · cited 3×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundWang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
Bueno, O. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.23.6341 · Cited by 774
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761 · cited 1×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundMummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 6×
“Recently, cardiac myocytes were derived from the induced pluripotent stem cells (iPSCs) of a patient with Noonan syndrome with multiple lentigines (formerly, LEOPARD syndrome) and found to be intrinsically hypertrophic [8].”
BackgroundMethodResultInfluentialSelf-citationGrowth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666 · cited 1×
“papers have described hECTs created from human iPSCs [31,32,34,35].”
Background
Cited by
Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond
Liu, C., Oikonomopoulos, A., Sayed, N., & Wu, J. C. (2018) · Development · doi:10.1242/dev.156166 · Cited by 267
“…tissue Dilated cardiomyopathy (Hinson et al., 2015; Tiburcy et al., 2017), heart failure (Tiburcy et al., 2017), hypertrophic cardiomyopathy (Cashman et al., 2016) Organ-on-chip Barth syndrome-associated cardiomyopathy (Wang et al., 2014) Skeletal muscle Engineered tissue Muscular dystrophy…”
BackgroundGoldfracht, I., Protze, S., Shiti, A., Setter, N., Gruber, A., Shaheen, N., Nartiss, Y., Keller, G., & Gepstein, L. (2020) · Nature Communications · doi:10.1038/s41467-019-13868-x · Cited by 263
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
Goldfracht, I., Efraim, Y., Shinnawi, R., Kovalev, E., Huber, I., Gepstein, A., Arbel, G., Shaheen, N., Tiburcy, M., Zimmermann, W. H., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.016 · Cited by 222
Smith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 169
“Reprinted with permission (Cashman et al., 2016).”
Human Cardiac Organoids for Disease Modeling
Nugraha, B., Buono, M. F., von Boehmer, L., Hoerstrup, S. P., & Emmert, M. Y. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1286 · Cited by 139
Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy
Ramaccini, D., Montoya-Uribe, V., Aan, F. J., Modesti, L., Potes, Y., Wieckowski, M. R., Krga, I., Glibetić, M., Pinton, P., Giorgi, C., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.624216 · Cited by 136
Biomaterializing the promise of cardiac tissue engineering
Pomeroy, J. E., Helfer, A., & Bursac, N. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.009 · Cited by 107
Organoids: a novel modality in disease modeling
Heydari, Z., Moeinvaziri, F., Agarwal, T., Pooyan, P., Shpichka, A. I., Maiti, T. K., Timashev, P. S., Baharvand, H., & Vosough, M. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00150-7 · Cited by 111
“1 3 potential to screen for new therapeutic approaches to treat this and related heart conditions [102].”
BackgroundCardiac Tissues From Stem Cells: New Routes to Maturation and Cardiac Regeneration
Campostrini, G., Windt, L. M., van Meer, B. J., Bellin, M., & Mummery, C. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318183 · Cited by 96
Anisotropic engineered heart tissue made from laser-cut decellularized myocardium
Schwan, J., Kwaczala, A. T., Ryan, T. J., Bartulos, O., Ren, Y., Sewanan, L. R., Morris, A. H., Jacoby, D. L., Qyang, Y., & Campbell, S. G. (2016) · Scientific Reports · doi:10.1038/srep32068 · Cited by 95
Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies
Brandão, K. O., Tabel, V. A., Atsma, D. E., Mummery, C. L., & Davis, R. P. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030320 · Cited by 104
“%) was combined with stromal cells (Cashman et al., 2016).”
Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures
Sacchetto, C., Vitiello, L., de Windt, L. J., Rampazzo, A., & Calore, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093404 · Cited by 91
Mayourian, J., Ceholski, D. K., Gonzalez, D. M., Cashman, T. J., Sahoo, S., Hajjar, R. J., & Costa, K. D. (2018) · Circulation Research · doi:10.1161/circresaha.117.311589 · Cited by 80
“Nevertheless, like others in the field, we continue to develop strategies to promote phenotypic maturation of human pluripotent stem cell–derived cardiomyocytes and hECTs including improved electrophysiology and contractility,(176) structurally advanced sarcomeres and evidence of T-tubule formation,(177) and the abili…”
BackgroundSelf-citationCriscione, J. D., Rezaei, Z., Cantu, C. M. H., Murphy, S. A., Shin, S. R., & Kim, D. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114840 · Cited by 87
Eschenhagen, T., & Carrier, L. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2214-0 · Cited by 86
Human Engineered Heart Tissue Models for Disease Modeling and Drug Discovery
Tani, H., & Tohyama, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.855763 · Cited by 83
From engineered heart tissue to cardiac organoid
Cho, J., Lee, H., Rah, W., Chang, H., & Yoon, Y. (2022) · Theranostics · doi:10.7150/thno.67661 · Cited by 74
“Increased expression of hypertrophic markers, aberrant calcium handling, and thickening of myocardium are characteristics of HCM patients [90]. hEHT models of HCM were generated with hiPSC-CMs containing BRAF [91], or PRKAG2 mutations, or electrical stimulation on hiPSC-CMs derived from a hypertension patient.”
MethodInfluentialMayourian, J., Cashman, T. J., Ceholski, D. K., Johnson, B. V., Sachs, D. M., Kaji, D. A., Sahoo, S., Hare, J. M., Hajjar, R. J., Sobie, E. A., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310796 · Cited by 67
“Furthermore, our model trends are consistent with our original hECT data on spontaneous beat rate variability—a proposed surrogate of arrhythmogenicity.(40,41) Most importantly, VW analyses predicted that hMSC supplementation (involving hMSC PS+HC mechanisms) did not adversely impact arrhythmogenesis and may even be a…”
ResultSelf-citationvan Mil, A., Balk, G. M., Neef, K., Buikema, J. W., Asselbergs, F. W., Wu, S. M., Doevendans, P. A., & Sluijter, J. P. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy208 · Cited by 65
“terized using iPSC-CMs, where an upregulation of a foetal gene programme, including ANP, was shown as well as arrhythmogenicity.(139,140) The model also showed the involvement of fibroblasts in developing the pathognomonic cardiomyocyte phenotype.”
MethodYouhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
Organoids in high-throughput and high-content screenings
Lampart, F. L., Iber, D., & Doumpas, N. (2023) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2023.1120348 · Cited by 66
“Finally, heart organoids are a useful model to study Barth syndrome, Dilated cardiomyopathy, acute myocardial infarction and Duchenne muscular dystrophy (Wang G. et al., 2014; Hinson et al., 2015; Cashman et al., 2016), while lung organoids model benefit Idiopathic pulmonary fibrosis and Cryptosporidium (Strikoudis et…”
MethodHuman heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes
Giacomelli, E., Mummery, C. L., & Bellin, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2546-5 · Cited by 60
Generating 3D human cardiac constructs from pluripotent stem cells
Liu, C., Feng, X., Li, G., Gokulnath, P., & Xiao, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103813 · Cited by 62
Saleem, U., Mannhardt, I., Braren, I., Denning, C. N., Eschenhagen, T., & Hansen, A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.12.011 · Cited by 62
“During the last decade, different technologies were established to generate contractile force in human induced pluripotent stem cell cardiomyocyte-derived engineered heart tissue (hiPSC-CM EHT) (Bielawski et al., 2016; Cashman et al., 2016; Hinson et al., 2016; Jackman et al., 2016; Kensah et al., 2013; Leonard et al.…”
BackgroundhiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery
Li, J., Hua, Y., Miyagawa, S., Zhang, J., Li, L., Liu, L., & Sawa, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238893 · Cited by 57
“Structural Cardiomyopathy Hypertrophic cardiomyopathy (HCM) MYH7, MYBPC3, ACTC, TNNT2, MYL2, TNNI3 [43,45,47]”
BackgroundA framework for developing sex-specific engineered heart models
Lock, R., Al Asafen, H., Fleischer, S., Tamargo, M., Zhao, Y., Radisic, M., & Vunjak-Novakovic, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00381-1 · Cited by 50
Current strategies of mechanical stimulation for maturation of cardiac microtissues
Carlos‐Oliveira, M., Lozano-Juan, F., Occhetta, P., Visone, R., & Rasponi, M. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00841-6 · Cited by 53
“Titin or BRAFmutations in iPSC-CMswere already used to model phenotypes characteristic of dilated cardiomyopathy and hypertrophic cardiomyopathy, respectively (Cashman et al. 2016; Hinson et al. 2015).”
MethodSilencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes
Dainis, A., Zaleta-Rivera, K., Ribeiro, A. J. S., Chang, A. C. H., Shang, C., Lan, F., Burridge, P. W., Liu, W. R., Wu, J. C., Chang, A. C. Y., et al. (2020) · Physiological Genomics · doi:10.1152/physiolgenomics.00021.2020 · Cited by 50
“tients with HCM have shown contractile dysfunction, including contractile arrhythmias and hypercontractility (5, 20, 38), as well as greater developed force and shorter twitch duration (10), in patient-derived cardiomyocytes as compared with wild-type controls.”
ResultJosowitz, R., Mulero-Navarro, S., Rodriguez, N. A., Falce, C., Cohen, N., Ullian, E. M., Weiss, L. A., Rauen, K. A., Sobie, E. A., & Gelb, B. D. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.018 · Cited by 45
“See also ated a 3D human engineered cardiac tissue (hECT) model, in which BRAF-mutant hECTs displayed increased twitch force and contraction and relaxation rates, and a lower excitation threshold compared with WT (Cashman et al., 2016).”
ResultSelf-citationHeart-on-a-chip systems: disease modeling and drug screening applications
Butler, D., & Reyes, D. R. (2024) · Lab on a Chip · doi:10.1039/d3lc00829k · Cited by 47
Genetics of paediatric cardiomyopathies
Ware, S. M. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000533 · Cited by 43
“Human engineered cardiac tissues from a patient with a BRAF mutation recapitulated the HCM phenotype, providing a cell culture approach to study disease mechanisms and therapies in vitro [57].”
Backgroundvan Spreeuwel, A. C. C., Bax, N. A. M., van Nierop, B. J., Aartsma-Rus, A., Goumans, M.-J. T. H., & Bouten, C. V. C. (2017) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-017-9737-1 · Cited by 38
“Current engineered cardiac disease models mainly incorporate genetically affected cells to capture a cardiac disorder [5, 6].”
Sewanan, L. R., & Campbell, S. G. (2019) · The Journal of Physiology · doi:10.1113/jp276753 · Cited by 39
“Mutations in non-sarcomeric cardiomyopathy genes, such those involved with ion channels, metabolic function, and growth pathways, are outside the scope of this review, but these too have been profitably studied in iPSC systems (Moretti et al. 2010; Cashman et al. 2016; Hinson et al. 2016; Joanne et al. 2016; Josowitz…”
BackgroundBrink, L., Grandela, C., Mummery, C. L., & Davis, R. P. (2020) · Stem Cells · doi:10.1002/stem.3110 · Cited by 38
“Although such heterotypic cell models are still in the early stages of development, 3D engineered cardiac tissues are being used to investigate contractile dysfunction caused by cardiomyopathies with promising results.(47,54,130,131)”
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers
Glavaški, M., Velicki, L., & Vučinić, N. (2023) · Medicina · doi:10.3390/medicina59081424 · Cited by 35
Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies
Seguret, M., Vermersch, E., Jouve, C., & Hulot, J. (2021) · Biomedicines · doi:10.3390/biomedicines9050563 · Cited by 33
Human cardiac organoids: A recent revolution in disease modeling and regenerative medicine
Roshanravan, N., Ghaffari, S., Bastani, S., Pahlavan, S., Asghari, S., Doustvandi, M. A., Razin, S. J., & Dastourı, M. (2023) · Journal of Cardiovascular and Thoracic Research · doi:10.34172/jcvtr.2023.31830 · Cited by 28
“18 In 2020, Lewis-Israeli et al presented a new method for producing human heart organoids using pluripotent stem cells.”
MethodWong, A. O.-T., Wong, G., Shen, M., Chow, M. Z.-Y., Tse, W. W., Gurung, B., Mak, S. Y., Lieu, D. K., Costa, K. D., Chan, C. W., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1305-y · Cited by 27
“Using hvCAS, we measured cellular action potential parameters and electrical conduction as a syncytium, and with 3D human ventricular cardiac tissue strips (hvCTS) that resemble cardiac trabecular muscles [16, 20, 21], we evaluated contractility.”
Self-citationCardiac macrotissues-on-a-plate models for phenotypic drug screens
Meyer, T., Tiburcy, M., & Zimmermann, W. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.03.002 · Cited by 32
Seguret, M., Davidson, P. M., Robben, S., Jouve, C., Pereira, C., Lelong, Q., Deshayes, L., Cerveau, C., Berre, M. L., Ribeiro, R. S. R., et al. (2024) · eLife · doi:10.7554/elife.87739 · Cited by 25
Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy
Santini, L., Palandri, C., Nediani, C., Cerbai, E., & Coppini, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105176 · Cited by 24
“Mutant engineered tissues showed increased cardiomyocyte size, higher increased contraction and relaxation rates associated with an evident arrhythmogenic substrate [216].”
BackgroundCamman, M., Joanne, P., Agbulut, O., & Hélary, C. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.040 · Cited by 29
“A simple approach relies on molding the substrate in the wells of a culture plate or in a PDMS mold to form hydrogels [9,145].”
MethodCardiac organoid: multiple construction approaches and potential applications
Yang, Z., Zhang, Y., Wang, J., Yin, J., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00783a · Cited by 26
Thermal response of multi-layer UV crosslinked PEGDA hydrogels
Khalili, M. H., Afsar, A., Zhang, R., Wilson, S., Dossi, E., Goel, S., Impey, S., & Aria, A. I. (2022) · Polymer Degradation and Stability · doi:10.1016/j.polymdegradstab.2021.109805 · Cited by 22
Microphysiological systems for human aging research
Park, S., Laskow, T. C., Chen, J., Guha, P., Dawn, B., & Kim, D. (2024) · Aging Cell · doi:10.1111/acel.14070 · Cited by 23
“…between aging and various age-related diseases, including cancer (Kim et al., 2020), retinal disease (Fligor et al., 2018), cardiovascular disease (Cashman et al., 2016; Wang et al., 2014), brain disease (Lancaster et al., 2013; Mariani et al., 2015), or bone-related diseases (Nguyen-Ngoc et al.,…”
BackgroundProgress of organoid platform in cardiovascular research
Du, X., Jia, H., Chang, Y., Zhao, Y., & Song, J. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.043 · Cited by 29
“It should be noted that HCM is also prevalent in patients with heart-facial-skin syndrome (CFCS), a genetic disorder characterized by abnormal signaling in the RAS/MAPK signaling cascade [18].”
BackgroundInfluentialHuman Induced Pluripotent Stem Cells as a Disease Model System for Heart Failure
Deicher, A., & Seeger, T. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00497-5 · Cited by 23
Disease modeling and functional screening using engineered heart tissue
Mills, R. J., Voges, H. K., Porrello, E. R., & Hudson, J. E. (2017) · Current Opinion in Physiology · doi:10.1016/j.cophys.2017.08.003 · Cited by 20
Advances in 3D Organoid Models for Stem Cell-Based Cardiac Regeneration
Martin, M., Gähwiler, E. K. N., Generali, M., Hoerstrup, S. P., & Emmert, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065188 · Cited by 21
“In addition, the HCM phenotype became apparent in BRAF-mutant EHTs, which demonstrated increased tissue size and arrhythmic pacing [71].”
BackgroundSwimming toward solutions: Using fish and frogs as models for understanding RASopathies
Patterson, V. L., & Burdine, R. D. (2020) · Birth Defects Research · doi:10.1002/bdr2.1707 · Cited by 16
Generation and applications of cardiac spheroids
Idais, D., Roche, C. D., Kalogianni, G., Polonchuk, L., & Gentile, C. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00024-y · Cited by 15
“Thanks to the use of induced pluripotent stem cells (iPSCs) 81 – 83 , it is possible to use patient-speci fi c stem cells to generate CSs or similar 3D microtissues of non-spheroidal morphology that are speci fi c to and compatible with a given patient 84,85 .”
Heart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease
Khosravi, R., & Radisic, M. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01255-1 · Cited by 18
“Expression of the two variants resulted in a synergistic upregulation of force production, with the MLP variant acting as a modifier that exacerbated the HCM phenotype 34 .”
InfluentialThree-dimensional cardiac models: a pre-clinical testing platform
Groen, E., Mummery, C. L., Yiangou, L., & Davis, R. P. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230444 · Cited by 14
Sayegh, M. N., Fernandez, N., & Cho, H. C. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00161.2019 · Cited by 11
Mashali, M. A., Deschênes, I., & Saad, N. S. (2025) · Children · doi:10.3390/children12060669 · Cited by 10
Dog as the experimental model: Laboratory uses of dogs in the United States
Ward, S. L. (2022) · ALTEX · doi:10.14573/altex.2109101 · Cited by 11
“…tissue is a promising emerging technology with the potential to replace some animal use in cardiovascular research while overcoming issues with extrapolating data between species (Cashman et al., 2016; Gähwiler et al., 2021; Li et al., 2018; Simon and Masters, 2020; Turnbull et al., 2014, 2018).”
BackgroundPooria, A., Pourya, A., & Gheini, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28330 · Cited by 10
From Human Pluripotent Stem Cells to 3D Cardiac Microtissues: Progress, Applications and Challenges
Branco, M. A., Cabral, J. M. S., & Diogo, M. M. (2020) · Bioengineering · doi:10.3390/bioengineering7030092 · Cited by 11
Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation
Chen, M., Zhang, T., Yang, S., Niu, Y., Ge, Y., Chen, Z., Zhang, J., Pu, Y., Gu, Z., & Liang, G. (2025) · Cells · doi:10.3390/cells15010007 · Cited by 10
“For instance, patient-derived hPSCs carrying mutations in α -actin 2 (ACTN2) [60], MYH7 [61], MYBPC3 [62], BRAF [63], and PRKAG2 [64] were used to construct directed-assembly hCOs, respectively.”
Strash, N., DeLuca, S., Carattini, G. L. J., Chen, Y., Wu, T., Helfer, A., Scherba, J. C., Wang, I., Jain, M., Naseri, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh2598 · Cited by 10
“…PSC (hiPSC)–CMs with germline BRAF-activating mutations (T599R and Q257R) displayed a phenotype reflective of hypertrophic cardiomyopathy ( 28 , 29 ), while in vivo mouse experiments have shown that transgenic CM–specific BRAF-V600E expression is sufficient to drive cardiac hypertrophy ( 16 )…”
BackgroundApplication of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies
Zhang, J., Chou, O. H. I., Tse, Y.-L., Ng, K., & Tse, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158132 · Cited by 8
Uncovering Inherited Cardiomyopathy With Human Induced Pluripotent Stem Cells
Jiang, X. D., Chen, Y., Liu, X., Ye, L., Yu, M., Shen, Z., Lei, W., & Hu, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672039 · Cited by 9
“Researchers have found that its mutations can cause pro-fibrotic phenotype, enhanced susceptibility to arrhythmias, aberrant MEK1/2 signaling and sarcomere disorders, and eventually lead to HCM (Cashman et al., 2016; Josowitz et al., 2016; Jaffré et al., 2019).”
BackgroundWu, H., Hamilton, C., Porritt, H., Winbo, A., & Zeltner, N. (2024) · The Journal of Physiology · doi:10.1113/jp286416 · Cited by 7
“Biological polymers used in hydrogel formation include gelatin methacryol (GelMA) (Chalard et al., 2022; Feric et al., 2019), fibrin (Navaee et al., 2023; Prondzynski et al., 2019) or collagen (Cashman et al., 2016).”
Bufi, S., & Santoro, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910690 · Cited by 10
“…the myocardium and of the related functional effects, such as An alternative approach to overcome these limitations is described by Cashman et al. [23], who proposed Cardiomyocytes derived either from a patient and control iPSC line (iPSC-CM) were assembled in MT in a co-culture with primary…”
MethodSynthetic embryology of the human heart
Paredes-Espinosa, M. B., & Paluh, J. L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1478549 · Cited by 8
Costa, K. D., Wong, A. O. T., Mak, S. Y., Roberts, E. G., Keung, W., Correia, C., Walentinsson, A., Christoffersson, J., Cheung, A., Lieu, D. K., et al. (2024) · bioRxiv · doi:10.1101/2024.08.27.609034 · Cited by 5
“In contrast to prior cardiac disease modeling approaches focused on genetic mutations, 20, 42, 43 this study demonstrates the use of biologics for induction of disease without requiring patient-specific human induced pluripotent stem cells.”
ResultSelf-citationKim, Y. H., Son, Y. H., Choi, Y., Kim, M. S., Park, S., & Lee, K. Y. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01249-6 · Cited by 8
“Hypertrophic cardiomyopathy (HCM) caused by mutations in MYH7, MYBPC3, PRKAG2, ACTN2, or BRAF is associated with sarco-meric disarray, hypercontractility, increased Ca² ⁺ sensitivity, and prolonged APD 111 – 113 .”
The updated view on induced pluripotent stem cells for cardiovascular precision medicine
Wang, Y., Lei, W., Yang, J., Ni, X., Ye, L., Shen, Z., & Hu, S. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02530-5 · Cited by 5
Vermersch, E., Neuvendel, S., Jouve, C., Ruiz‐Velasco, A., Pereira, C., Seguret, M., Cattin, M., Lotfi, S., Dorval, T., Berson, P., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.161356 · Cited by 5
“The cell-matrix mix (100 μ L/mold) was seeded in a flexible PDMS mold and placed at 37°C and 5% CO 2 (26, 45, 46).”
MethodA patient-specific engineered tissue model of BAG3-mediated cardiomyopathy
Morsink, M. A. J., Wang, B. Z., Watkins, J. M., Zhuang, R. Z., Zhang, X., Chesnais, F., Chen, C., Lock, R. I., Fine, B. M., & Vunjak‐Novakovic, G. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314251371296 · Cited by 4
“50 DCM has been recapitulated in EHTs with titin (TTN) mutations with clear deficits in active force generation, 51 similar to the decrease in active force generation in our BAG3 patient-derived EHTs.”
Jasim, S. A., Bokov, D. O., Suksatan, W., Alsaikhan, F., Jawad, M. A., Sharma, S. K., Chupradit, S., & Thangavelu, L. P. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221021122603 · Cited by 5
Cardiac Disease Modeling with Engineered Heart Tissue
Cai, L., Wang, R., & Zhang, D. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_681 · Cited by 5
Bruyneel, A. A. N., Muser, T., Parthasarathy, V., Feyen, D. A. M., & Mercola, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-20047-3_2 · Cited by 3
Human Cardiac Organoids: Quantification and Qualification in Cardiovascular Studies
Liu, Y., Abraham, S., & Xu, H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100017 · Cited by 2
“This technique has enabled the study of human heart disease and the testing of potential therapies in a more physiologically relevant context [30].”
Chu, X., Wang, M., Qiu, X., Huang, Y., Li, T., Otieno, E., Li, N., Luo, L., & Xiao, X. (2021) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37298 · Cited by 2
Rupert, C. E., López, J. E., Cortez-Toledo, E., Cabrera, O. D. L. C., Chesler, N. C., Simpson, P. C., Campbell, S. G., & Baker, A. J. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00279.2022 · Cited by 2
Mechanisms, Diagnosis, and Therapy of Cardiac Arrhythmia
Madadi, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00004-1 · Cited by 2
Toward the Development of Novel Therapy for Hypertrophic Cardiomyopathy
Matsuura, K. (2018) · International Heart Journal · doi:10.1536/ihj.18-466 · Cited by 2
Seguret, M., Davidson, P. M., Robben, S., Jouve, C., Pereira, C., Cerveau, C., Berre, M. L., Ribeiro, R. S. R., & Hulot, J. (2023) · eLife · doi:10.7554/elife.87739.1 · Cited by 4
Modeling the Heart With Novoheart’s Myheart™ Platform
Wong, G., Costa, K. D., Fermini, B., & Li, R. A. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0003 · Cited by 2
Self-citationRuiz‐Velasco, A., Jouve, C., Deshayes, L., Kohlhaas, M., Maack, C., & Hulot, J. (2026) · Pediatric Research · doi:10.1038/s41390-026-05208-9 · Cited by 2
Swelling Analysis of Thermal and Chemical Crosslinked Konjac Glucomannan/Gellan Gum Cardiac Patch
Loureiro, J., Miguel, S. P., Galván-Chacón, V., Patrocinio, D., Sanchez-Margallo, F. M., Pagador, J. B., Ribeiro, M. P., & Coutinho, P. (2021) · E-Health and Bioengineering Conference (EHB) · doi:10.1109/ehb52898.2021.9657686 · Cited by 1
Human-Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissues
Nakane, T., Masumoto, H., & Keller, B. B. (2018) · InTech eBooks · doi:10.5772/intechopen.71621
“Cashman and colleagues created 3D human engineered cardiac tissue model of HCM using human cardiomyocytes yielded by directed differentiation of iPSCs established from a patient with CFCS carrying an activated BRAF mutation [53].”
BackgroundModeling Cardiomyopathies with iPSCs
Hulot, J. (2019) · Current human cell research and applications · doi:10.1007/978-981-13-3672-0_5
Induced Pluripotent Stem Cells
van Mil, A., Neef, K., Balk, G. M., Buikema, J. W., Sluijter, J. P. G., & Doevendans, P. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_26
Strash, N., DeLuca, S., Carattini, G. L. J., Chen, Y., Scherba, J. C., Jain, M., Naseri, R., Wu, T., & Bursac, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.28.482357
Microfabricated Systems for Cardiovascular Tissue Modeling
Knee‐Walden, E. J., Wagner, K. T., Wu, Q., Rafatian, N., & Radisic, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-86140-7_10
Seguret, M., Davidson, P., Robben, S., Jouve, C., Pereira, C., Cerveau, C., Berre, M. L., Ribeiro, R. S. R., & Hulot, J. (2023) · eLife · doi:10.7554/elife.87739.1.sa3
Human Stem Cell-Derived Cardiac Organoid-Like Structures: Generation and Applications
Giraud, M., Ahmed, S., & Ullrich, N. D. (2023) · Springer eBooks · doi:10.1007/978-981-99-0722-9_15
Vascularisation of cardiac organoids
Kakarla, S. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20621629
Hsieh, J., Hall, M. A. L., Shameem, M., Erñst, P., Kamdar, F. D., Singh, B. N., Meisel, R. L., & Ogle, B. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.08.606705
Kleemann, K. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10816
Taghiyev, Z. T., Arneth, B. M., Altrawy, A., Mohamed, R., Ghazy, A., Hamdy, D., & Sabit, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29890-5.00001-4
Tissue engineered models of the human heart
Windt, L. M. (2025) · Leiden Repository (Leiden University)
Li, J., Peng, W., Kwok, M., Ding, H., Zhuo, D., Gurung, B., Lakhani, I. R., Yu, H., Poon, E. N.-Y., Li, R. A., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08639-8
Etude des anomalies du métabolisme énergétique associées au syndrome de Noonan
Branka, S. (2019) · theses.fr (ABES) · doi:10.70675/b0d081a3z3492z4457za237zcabd6ccc0a76
Metadata
- Authors
- Cashman, T. J., Josowitz, R., Johnson, B. V., Gelb, B. D., & Costa, K. D.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Costa, Kevin D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-19
- Volume
- 11
- Issue
- 1
- Pages
- e0146697
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4718533
- OpenAlex
- W2372676601
- Cited by
- 101
- References
- 43
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 8 · 2017: 6 · 2016: 3
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association (12PRE12060254)
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL113499, R01HL113499, F30HL118923, HHSN268201000045C)
- National Institute of General Medical Sciences (T32GM008553)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD075735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, BRAF mutation, cardiofaciocutaneous syndrome, RASopathies, RAS/MAPK pathway, induced pluripotent stem cells, cardiomyocyte differentiation, stromal co-culture, twitch force, atrial natriuretic peptide, arrhythmogenic substrate, passive stiffness, disease modeling, sudden cardiac death
- MeSH terms
- Cardiomyopathy, Hypertrophic, Cell Differentiation, Cells, Cultured, Humans, Mutation, Myocardial Contraction, Atrial Natriuretic Factor, Tissue Engineering, Myocytes, Cardiac, Proto-Oncogene Proteins B-raf, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.